FDA OKs Ingrezza for treating chorea associated with Huntington’s; Abivax inks agreement for up to $163M in debt financing

The FDA on Fri­day ap­proved Neu­ro­crine Bio­sciences’ In­grez­za to treat adults with chorea as­so­ci­at­ed with Hunt­ing­ton’s dis­ease.

In­grez­za, al­so known as val­be­nazine, was first ap­proved by the FDA in 2017 to treat tar­dive dysk­i­ne­sia, which can cause un­con­trol­lable jerk­ing move­ments in the face and body. Chorea is al­so a con­di­tion that can gen­er­ate ran­dom and sud­den jerk­ing move­ments in the body and can oc­cur in pa­tients with Hunt­ing­ton’s dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.